Charity auction raises $250,000 for Children's Miracle Network Hospitals
NEW YORK, Aug. 12, 2025 /PRNewswire/ -- Children's Miracle Network Hospitals (CMN Hospitals) announced that...
Check out Exhale’s new premium Delta 8 flower strains: Hawaiian Haze for euphoria & Northern Lights for relaxation. Best option for balanced highs & therapeutic benefits.
Check out Exhale’s new premium Delta 8 flower strains: Hawaiian Haze for euphoria & Northern Lights for relaxation. Best option for balanced highs & therapeutic benefits.
The opinion will now be referred to the European Commission for final regulatory decision on donanemab
INDIANAPOLIS, July 25, 2025 /PRNewswire/ -- Eli Lilly and...
SHENZHEN, China, July 21, 2025 /PRNewswire/ -- From September 1 to 3, 2025, SIAL Shenzhen 2025, an exclusive gateway to South Asia's dynamic food and...
PALO ALTO, Calif., July 15, 2025 /PRNewswire/ -- Lucile Packard Children's Hospital Stanford, the cornerstone of Stanford Medicine Children's Health, is proud to announce...
NEWTON, Mass., July 10, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), will present new findings at the upcoming Alzheimer's Association International Conference (AAIC®) 2025 in Toronto. The presentations include a cost savings analysis of the use of pTau217 as a screening tool in Acumen’s Phase 2 ALTITUDE-AD trial of sabirnetug as well as a nonclinical study evaluating the relative selectivity of sabirnetug to targeting AβOs versus Aβ monomers. The conference will be held July 27-31, 2025, both in-person and online.